Financial

Severe Heart Failure Treatment: FineHeart Successfully Raises €15 million Series B funding With Industrial and Independent Investors

The First In Human implantation of the ICOMS FLOWMAKER® is assured following this financing BORDEAUX, France–(BUSINESS WIRE)–FineHeart S.A, a preclinical medical device company that has developed the ICOMS FLOWMAKER®, an Implantable Cardiac Output Management System designed to address the unmet need of patients suffering from severe heart failure, today announced the […]

VOTIS Subdermal Imaging Technologies Raises US$2.5 Million

Share Offering Over-subscribed JERUSALEM, June 1, 2021 /PRNewswire/ — VOTIS Subdermal Imaging Technologies, Ltd. announced today that it has raised US$2.5 million in a private placement of equity to a consortium of investors in Israel, Italy, the UK, and the US. Proceeds are being used to complete development of the company’s suite of medical devices and […]

Retia Medical Announces Bernd Saugel has Joined the Clinical Advisory Board

VALHALLA, N.Y., June 01, 2021 (GLOBE NEWSWIRE) — Retia Medical, an innovator in hemodynamic monitoring that helps clinicians guide care to prevent complications from high-risk surgeries such as heart attacks, strokes, and acute kidney injuries, today announced that Bernd Saugel, MD, EDIC joins other distinguished clinicians on Retia Medical’s Clinical […]

Abiomed Acquires preCARDIA, a Breakthrough Medical Device Company, to Improve Outcomes for Heart Failure Patients

DANVERS, Mass.–(BUSINESS WIRE)–Abiomed (NASDAQ: ABMD) has acquired preCARDIA, developer of a proprietary catheter and controller that will complement Abiomed’s product portfolio to expand options for patients with acute decompensated heart failure (ADHF). The preCARDIA system is uniquely designed to rapidly treat ADHF-related volume overload by effectively reducing cardiac filling pressures and […]

Alnylam Completes Enrollment in APOLLO-B Phase 3 Study of Patisiran in Transthyretin-Mediated (ATTR) Amyloidosis Patients with Cardiomyopathy

− APOLLO-B is the Industry’s Furthest Progressed Randomized, Double-Blind, Placebo-Controlled Pivotal Study of an Investigational TTR Silencer in Hereditary and Wild-type ATTR Amyloidosis with Cardiomyopathy − − Topline Results Expected in Mid-2022 − CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has achieved […]

Verve Therapeutics Appoints Leading Biotechnology Executive Michael MacLean to its Board of Directors

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Michael F. MacLean, chief financial officer (CFO) of Avidity Biosciences, has joined the company’s board of directors. “Mike is a highly experienced executive with an […]